Statins and breast cancer: A smoking gun or guilt by association?

Expert Opinion on Drug Safety

Volumn 5, Issue 5, 2006, Pages 599-601

  Ahmed, Mohamed H ^a   Osman, Meissa M ^a   Alokail, Majed S ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Breast cancer; Statin

Indexed keywords

ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ATORVASTATIN; CHOLESTEROL; ESTRADIOL; ESTROGEN; FAS LIGAND; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BCL 2; PROTEIN P53; ROSUVASTATIN; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CLINICAL TRIAL; COLORECTAL CANCER; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; LONG TERM CARE; LUNG CANCER; MELANOMA; META ANALYSIS; MYOPATHY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRESCRIPTION; PROSTATE CANCER; PUBLIC HEALTH; SYSTEMATIC REVIEW; UNITED STATES; UPREGULATION; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; EXPERT WITNESS; FEMALE;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; EXPERT TESTIMONY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33747490037     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.5.599     Document Type: Editorial

References (11)

1. AHMED MH: Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH). Scand. J. Gastroenterol. (2006) 41:631.
2. AHMED MH, OSMAN KA: Tamoxifen induced-non-alcoholic steatohepatitis (NASH): Has the time come for the oncologist to be diabetologist. Breast Cancer Res. Treat. (2006) 97:223-224.
3. COOGAN PF, ROSENBERG L, PALMER JR, STROM BL, ZAUBER AG, SHAPIRO S: Statin use and risk of breast and prostate cancer. Epidemiology (2002) 13:262-267.
4. ADDEO R, ALTUCCI L, BATTISTA T et al.: Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors. Biochem. Biophys. Res. Commun. (1996) 220:864-870.
5. MUCK AO, SEEGER H, WALLWIENER D: Inhibitory effect of statins on the proliferation of human breast cancer cells. Int. J. Clin. Pharmacol. Ther. (2004) 42:695-700.
6. JACOBS D, BLACKBURN H, HIGGINS M et al.: Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation (1992) 86:1046-1060.
7. NEWMAN TB, HULLEY SB: Carcinogenicity of lipid-lowering drugs. JAMA (1996) 275(1):55-60.
8. BLAIS L, DESGAGNE A, LELORIER J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch. Intern. Med. (2000) 160:2363-2368.
9. DEMIERRE MF, HIGGINS PD, GRUBER SB, HAWK E, LIPPMAN SM: Statins and cancer prevention. Nat. Rev. Cancer (2005) 5(12):930-942.
10. BONOVAS S, FILIOUSSI K, TSAVARIS N, SITARAS NM: Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol. (2005) 23:8606-8612.
11. CAULEY JA, MCTIERNAN A, RODABOUGH RJ et al.; Women's Health Initiative Research Group: Statin use and breast cancer: prospective results from the Women's Health Initiative. J. Natl. Cancer Inst. (2006) 98:700-707.